PeerVoice Oncology & Haematology Video

Linda Lee, MD, FRCPC / Jacob Rullo, MD, PhD, FRCSC - Managing MEK-Inhibitor–Associated Retinopathy in Metastatic Melanoma: An Expert Discussion

Erika Hamilton, MD - Safety First: Recognising and Responding to Toxicities Associated With TROP2-Directed Therapies in Metastatic Breast Cancer

Versha Banerji, MD, FRCPC - Raising the Bar: The Evolving Role of BTK Inhibitors in CLL Management

John Mascarenhas, MD - Working With Our Patients as Partners in Care: Addressing Disease- and Treatment-Related Burdens Associated With Cytopenic Myelofibrosis

Paul Wheatley-Price, BSc, MBChB, MD, FRCP (UK) / Parneet K. Cheema, MD - Addressing Key Challenges to Improve Outcomes in Patients With NSCLC With Rare Actionable Genomic Alterations

Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML

Maurie Markman, MD - Testing Impacts Treatment: Applying Best Practices in HER2 Assessment in Solid Tumours

Neal Shore, MD, FAC - Advancing Care for mCRPC With Life-Prolonging Therapies: Existing and Emerging Roles for Radiopharmaceuticals

Richard Kim, MD - The Modern Art of Sequencing Later Lines of Treatment for Advanced Colorectal Cancer: Exploring Case Scenarios With the Experts

Ffion Davies, MBChB, FRCPCH, FRCEM - Managing Major Bleeding in Patients Receiving DOACs: Data, Developments, and Decision-Making in the ED

Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice

Karin Jordan, MD, PhD - Applying Foresight to Optimise Emesis Control in Patients Receiving Antibody-Drug Conjugates

Elena Castro, MD, PhD - Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences

Karin Jordan, MD, PhD - Practical Protocols for Preventing and Managing Antibody-Drug Conjugate-Associated Nausea and Vomiting

Peter Schmid, FRCP, MD, PhD - Staying at the Forefront of HER2 and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer

Simron Singh, MD, MPH - Addressing the Challenges of Treating Highly Proliferative Neuroendocrine Tumours: Review of the Latest Evidence

Andrea Necchi, MD - Practical Considerations for ADC-ICI Combinations in Advanced Urothelial Carcinoma: Identifying and Managing Adverse Events

Christine Brezden-Masley, MD, PhD, FRCPC - Breaking Barriers: Expert Guidance on Best Strategies for Biomarker Testing in Gastric and GEJ Cancers

Diana N. Ionescu, MD - Pathological Assessment of HER2 Status in Gastric and Gastroesophageal Cancers: Important Steps That Can Impact Outcomes

Alon Altman, MD, FRCSC - Upping the Ante in Advanced Endometrial Cancer Care: Optimizing the Use of Immunotherapy to Improve Patient Outcomes

Elizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What’s Next for Patients With HER2+ Gastric Cancer

Stephanie Snow, MD, FRCPC - Mastering HER2 in GI Malignancies: Immunotherapy and Chemotherapy Backbones for Optimal Patients Outcomes

Christine Brezden-Masley, MD, PhD, FRCPC - Navigating HER2+ Early Breast Cancer Care: A Multidisciplinary Roadmap to Better Survival

Jacqueline S. Garcia, MD - Small Words, Big Differences: Best Practices in Supportive Care for Patients With AML

Brandon Blue, MD - Challenging Racial Disparities in Multiple Myeloma Treatment and Outcomes: Local Solutions to Address an Endemic Problem